

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WAI YUEN TONG MEDICINE HOLDINGS LIMITED

(位元堂藥業控股有限公司*)

(Incorporated in Bermuda with limited liability)

(Stock Code: 897)

INSIDE INFORMATION POSITIVE PROFIT ALERT

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules and Inside Information Provisions under Part XIVA of the SFO.

The Board wishes to inform the shareholders and potential investors of the Company that based on a preliminary review of the draft unaudited consolidated management accounts of the Group for the financial year ended 31 March 2022 and the information currently available to the Board, the Group expects to record a loss attributable to owners of the parent of not more than HK\$140.0 million for the financial year ended 31 March 2022 as compared to a loss attributable to owners of the parent for the financial year ended 31 March 2021 of approximately HK\$376.0 million as published in the Company's 2021 annual report.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

This announcement is made by Wai Yuen Tong Medicine Holdings Limited (位元堂藥業控股有限公司*) (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

The board of directors (the “**Board**” or the “**Directors**”) of the Company wishes to inform the shareholders and potential investors of the Company that based on the preliminary review of the draft unaudited consolidated management accounts of the Group for the financial year ended 31 March 2022 and the information currently available to the Board, the Group is expected to record a loss attributable to owners of the parent of not more than HK\$140.0 million for the financial year ended 31 March 2022 as compared to a loss attributable to owners of the parent for the financial year ended 31 March 2021 of approximately HK\$376.0 million as published in the Company’s 2021 annual report. Such reduction in loss is mainly attributable to the effect of the loss on disposal on the Group’s investment in Easy One Financial Group Limited, a former associate of the Group, of approximately HK\$237.7 million recorded for the financial year ended 31 March 2021 and the absence of such loss for the financial year ended 31 March 2022.

As the Company is still in the course of finalizing its annual results for the financial year ended 31 March 2022, the information contained in this announcement is only based on the preliminary review of the draft unaudited consolidated management accounts of the Group for the financial year ended 31 March 2022 and the information currently available to the Board and subject to finalization of valuation results of investment properties and financial instruments by independent professional valuers, which have yet to be confirmed, reviewed or audited by the independent auditors or the audit committee of the Company. Details of the performance of the Group for the financial year ended 31 March 2022 will be disclosed in the annual results announcement of the Company which is expected to be published by end of June 2022 in accordance with the requirements under the Listing Rules.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
WAI YUEN TONG MEDICINE HOLDINGS LIMITED
(位元堂藥業控股有限公司*)
Tang Ching Ho
Chairman and Executive Director

Hong Kong, 10 June 2022

As at the date of this announcement, the executive directors of the Company are Mr. Tang Ching Ho, Ms. Tang Wai Man and Ms. Law Man Yee, Anita, and the independent non-executive directors of the Company are Mr. Leung Wai Ho, Mr. Siu Man Ho, Simon, Mr. Cho Wing Mou and Mr. Li Ka Fai, David.

* *For identification purpose only*